Weinblatt et al. AMPLIFIED trial. No difference in response rates of RA to adalimumab or abatacept based on dual seropos

Social Author Image

https://pbs.twimg.com/profile_images/1389468430160510976/sooz0Ud3_normal.jpg

Tweet Author

Social Author Name

Richard Conway

Tweet Content

Weinblatt et al. AMPLIFIED trial. No difference in response rates of RA to adalimumab or abatacept based on dual seropositivity/shared epitope status. Fits with my priors and refutes a previous pilot study. @RheumNow #ACR24 Abstr#2671 https://t.co/OUwnlsP6jU https://t.co/RBN6ivSKDr

Links

Subcutaneous Abatacept vs Adalimumab Head-to-Head Comparison in Adults with Ear… https://acrabstracts.org/abstract/subcutaneous-abatacept-vs-adalimumab-head-to-…

https://x.com/RichardPAConway/status/1858903813266305537/photo/1

Show on Archive Page

On

Display in Search Results

On

PDQ

Off

Topics

Weinblatt et al. AMPLIFIED trial. No difference in response rates of RA to adalimumab or abatacept based on dual seropos

Do you get our email newsletter?